Nov 19, 2018 - Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
Nov 09, 2018 - Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Nov 07, 2018 - Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
Nov 06, 2018 - Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
Nov 02, 2018 - We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Nov 02, 2018 - Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Nov 02, 2018 - Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Nov 01, 2018 - Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
Nov 01, 2018 - Barclays issues rating change for SNY
Oct 31, 2018 - SNY earnings call for the period ending September 30, 2018.